Opthea is committed to improving vision in patients suffering from retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in Phase 2 wet AMD and DME clinical trials.



Wet AMD is the leading cause of blindness in the developed world in people aged over 50 years. It is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss.

Learn More


Opthea’s technology is centred on two members of the Vascular Endothelial Growth Factor (VEGF) family of proteins, VEGF-C and VEGF-D, and their activation of VEGF receptors.These proteins promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3, and lymphatic vessel development (lymphangiogenesis), by activation of VEGFR-3.

Learn More


Both wet AMD and DME are associated with vascular dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Vessel growth and vascular leakage are primarily driven by members of the vascular endothelial growth factor (VEGF) family, which comprises 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF).

Learn More


OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Learn More


Opthea has completed a Phase 2b clinical trial in the US and Europe investigating OPT-302 in wet AMD patients. Opthea has completed enrolling patients in a Phase 2a clinical trial in patients with DME and is planning a Phase 3 trial continuing investigation of OPT-302 in wet AMD patients globally.


With trials progressing
and initial data
looking promising,
we are confident
the end of this
disease is within

Opthea Researcher


Opthea Corporate Presentation for the 2020 JPMorgan Conference

13th January 2020

Opthea to present its updated corporate presentation at the January 2020 JPMorgan conference in San Francisco.

Read More

Opthea Completes Recruitment in Phase 2a Clinical Trial of OPT-302 for Diabetic Macular Edema

7th January 2020

Opthea announces completion of patient recruiment into its Phase 2a trial evaluating the safety and efficacy of OPT-302 for the treatment of DME.

Read More

Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco

11th October 2019

Opthea announces at OIS additional data supports recent reporting of superiority with OPT-302 combination therapy over ranibizumab in mean changes in best-corrected visual acuity (BCVA) from baseline to week 24 in treatment naïve patients with choroidal neovascularisation (CNV) secondary to (wet) AMD.

Read More

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302

7th August 2019

Opthea announces positive Phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis® monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD).

Read More

Listen to the Investor Call